Press release

Royalty Pharma Announces Expansion of Senior Leadership Team

Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today

articleRoyalty Pharma PlcDecember 15, 20224/company/royalty-pharma-plc/news/royalty-pharma-announces-expansion-of-senior-leadership-team-2022-12-15
Royalty Pharma Announces Expansion of Senior Leadership Team

About this update from Royalty Pharma Plc

[{"type":"text","content":"Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient lives. The following promotions are effective January 1, 2023, and each individual will join the Senior Leadership Committee: Sara Klymkowsky will be promoted to Senior Vice President, Research & Investments. Sara has been an integral member of the Research & Investments team since joining Royalty Pharma in 2012. She has played a key role in executing many of Royalty Pharma’s most important transactions, including investments in the Vertex cystic fibrosis franchise, Tysabri and Trelegy.Brienne Kugler will be promoted to Senior Vice President, Research & Investments. Brienne has been a key member of the Research & Investments team since joining Royalty Pharma in 2014. She has played a major role in executing many of Royalty Pharma’s most important transactions, including multiple Biohaven investments, Tremfya and Evrysdi.Alessandra Sassun will be promoted to Senior Vice President, Head of Human Capital. Alessandra joined Royalty Pharma in 2020 and is responsible for overseeing Royalty Pharma’s human resource planning, professional development and performance management. “We are delighted to announce the promotions of Sara, Brienne and Alessandra as well as their addition to Royalty Pharma’s Senior Leadership Committee,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Sara and Brienne have been exceptionally strong contributors to Royalty Pharma’s success, and have led the sourcing, engagement, diligence, and execution of many of our most important royalty transactions. Alessandra brings deep experience and diverse perspectives from her many years overseeing human capital at leading investment firms. I am confident our strengthened leadership team is well positioned to execute on our mission of accelerating innovation in life sciences and transforming patient lives while delivering value for all of our stakeholders.” About Royalty Pharma Founded in 1996, Royalty Pharma is the larges...

More updates from Royalty Pharma Plc